Background
Methods
Study design
Urine collection and patients’ information
Characteristic | Case (n = 167) | Control (n = 105) |
---|---|---|
Age, yrs. | ||
Median | 67 | 53 |
Range | 28–85 | 23–81 |
Sex, no. (%) | ||
Male | 135 (80.8) | 52 (49.5) |
Female | 32 (19.2) | 53 (50.5) |
Smoking History, no. (%) | ||
Current smoker | 38 (22.8) | NA |
Former smoker | 58 (34.7) | NA |
Non-smoker | 67 (40.1) | NA |
Missing | 4 (2.4) | |
Cytology, no. (%) | ||
Negative/Positive/Suspicious | 123 (73.6)/8 (4.8)/6 (3.6) | 105 (100) |
Missing | 30 (18.0) | |
Tumor Stage, no. (%) | ||
pTa/pT1/CIS | 126 (75.4)/25 (15.0)/6 (3.6) | NA |
Other | 10 (6.0) | NA |
Tumor Grade, no. (%) | ||
Low/High | 100 (59.9)/67 (40.1) | NA |
Risk Categories, no. (%) | ||
Low/Intermediate/High | 40 (24.0)/56 (33.5)/71 (42.5) | NA |
Characteristic | Recurrence-free (n = 86) | Recurrence (n = 72) |
---|---|---|
Age, yrs. | ||
Median | 67 | 66 |
Range | 30–84 | 28–83 |
Sex, no. (%) | ||
Male | 74 (86.1) | 52 (72.2) |
Female | 12 (13.9) | 20 (27.8) |
Smoking History, no. (%) | ||
Current smoker | 25 (29.1) | 12 (16.7) |
Former smoker | 34 (39.5) | 22 (30.6) |
Non-smoker | 26 (30.2) | 35 (48.6) |
Missing | 1 (1.2) | 3 (4.1) |
Recurrence Rate, no. (%) | 72 (45.6) | |
Time to recurrences, mos. | ||
Median/Range | 10/3–24 | |
Follow-up Urine Analyzed, no. | 312 | 113 |
Total Urine Analyzed, no. | 398 | 185 |
Cytology, no. (%) | ||
Negative/Positive/Suspicious | 67 (77.9)/6 (7.0)/2 (2.3) | 50 (69.5)/2 (2.8)/3 (4.1) |
Missing | 11 (12.8) | 17 (23.6) |
Tumor Stage, no. (%) | ||
pTa/pT1/CIS | 62 (72.1)/14 (16.3)/4 (4.6) | 55 (76.4)/11 (15.3)/2 (2.8) |
Other | 6 (7.0) | 4 (5.5) |
Tumor Grade, no. (%) | ||
Low/High | 48 (55.8)/38 (44.2) | 47 (65.3)/25 (34.7) |
Risk Categories, no. (%) | ||
Low/Intermediate/High | 23 (26.7)/25 (29.1)/38 (44.2) | 15 (20.8)/28 (38.9)/29 (40.3) |
Processing of urine samples for capture and enrichment of tumor cells
Urine DNA isolation
FGFR3 mutation analysis
Identification of best candidate epigenetic markers
Bisulfite DNA modification and methylation analysis
Assays
Target selection
Studies
% Sensitivity (Se) | % Specificity (Sp) | |
---|---|---|
Diagnosis set (n =272) | ||
HS3ST2 | 82.0 (137/167) | 21.20 (22/105) |
SEPTIN9 | 90.4 (151/167) | 67.6 (71/105) |
SLIT2 | 90.4 (151/167) | 18.1 (19/105) |
HS3ST2 + SEPTIN9 | 90.4 (151/167) | 72.4 (76/105) |
HS3ST2 + SLIT2 | 90.4 (151/167) | 34.3 (36/105) |
SEPTIN9 + SLIT2 | 91.0 (152/167) | 71.4 (75/105) |
HS3ST2 + SEPTIN9 + SLIT2 | 90.4 (151/167) | 75.2 (79/105) |
Multivariate analysis and further analyses
Diagnosis data
Results
Performance of FGFR3 assay alone, CMI alone and their combination to detect tumor stage and histological grade
A. Diagnosis study | Primary tumor (n = 167) | |||||
Markers | Tumor stage, % (no.) | Tumor grade, % (no.) | ||||
pTa (n = 126) | pT1 (n = 25) | CIS (n = 6) | Other (n = 10) | Low (n = 100) | High (n = 67) | |
FGFR3 | ||||||
All mutations | 46.0 (58) | 28.0 (7) | 16.7 (1) | 30.0 (3) | 53.0 (53) | 23.9 (16) |
S249C | 69.0 (40) | 42.8 (3) | 62.2 (33) | 62.5 (10) | ||
Y375C | 13.8 (8) | 28.6 (2) | 33.3 (1) | 17.0 (9) | 12.5 (2) | |
R248C | 10.3 (6) | 28.6 (2) | 100 (1) | 33.3 (1) | 11.3 (6) | 25.0 (4) |
G372C | 5.2 (3) | 5.7 (3) | ||||
S249C/R248C | 1.7 (1) | 1.9 (1) | ||||
S249C/Y375C | 33.3 (1) | 1.9 (1) | ||||
Methylation | 90.5 (114) | 100 (25) | 100 (6) | 90.0 (9) | 89.0 (89) | 100 (67) |
Combined markers | 94.4 (119) | 100 (25) | 100 (6) | 90.0 (9) | 94.0 (94) | 100 (67) |
B. Follow-up study | Recurrence (n = 72) | |||||
Markers | pTa (n = 55) | pT1 (n = 11) | CIS (n = 2) | Other (n = 4) | Low (n = 47) | High (n = 25) |
FGFR3 | ||||||
All mutations | 43.6 (24) | 36.4 (4) | 50.0 (2) | 46.8 (22) | 32.0 (8) | |
S249C | 58.3 (14) | 100 (4) | 54.6 (12) | 75.0 (6) | ||
Y375C | 20.8 (5) | 13.7 (3) | 25.0 (2) | |||
R248C | 16.7 (4) | 50.0 (1) | 22.7 (5) | |||
G372C | 4.2 (1) | 4.5 (1) | ||||
S249C/R248C | 50.0 (1) | 4.5 (1) | ||||
Methylation | 89.1 (49) | 90.9 (10) | 100 (2) | 50.0 (2) | 85.1 (40) | 96.0 (24) |
Combined markers | 96.4 (53) | 100 (11) | 100 (2) | 50.0 (2) | 93.6 (44) | 96.0 (24) |